Breaking News
Get 45% Off 0
Investors lost 37% by missing this ONE signal 😵
Read now

Agenus (AGEN) Reports In Line Loss In Q3, Revenues Lag

By Zacks Investment ResearchStock MarketsNov 07, 2017 11:56PM ET
www.investing.com/analysis/agenus-agen-reports-in-line-loss-in-q3-revenues-lag-200263621
Agenus (AGEN) Reports In Line Loss In Q3, Revenues Lag
By Zacks Investment Research   |  Nov 07, 2017 11:56PM ET
Saved. See Saved Items.
This article has already been saved in your Saved Items
 
 
AMZN
-3.29%
Add to/Remove from Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
AGEN
-8.30%
Add to/Remove from Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
LGND
-5.21%
Add to/Remove from Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
EXEL
+2.80%
Add to/Remove from Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
ADAP
-5.44%
Add to/Remove from Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 

Agenus Inc. (NASDAQ:AGEN) incurred loss of 37 cents per share in line with the Zacks Consensus Estimate. The figure came in narrower the year-ago loss of 47 cents.

Revenues of $3.4 million missed the Zacks Consensus Estimate of $4 million. Also, the top line was down from $4.4 million in the year-ago quarter.

So far this year, shares of Agenus have declined 15.1%, as against the industry’s growth of 3.3%.

Quarterly Highlights

Agenus' third-quarter research and development (R&D) expenses were up 19.5% to $25.8 million. However, general and administrative expenses were down slightly by 0.7% to $8.1 million.

Pipeline Update

Agenus is progressing well with various candidates in its pipeline. The company expects to complete phase I dose-escalation, and generate safety and pharmacodynamic data for its anti-CTLA-4 antibody AGEN1884 later in 2017. Also, it is planning to start combination trials of AGEN1884 and AGEN2034 by the year end.

Agenus separate business entity -AgenTus, will help enhance business focus, speed and efficiency towards the realization of breakthrough immuno-oncology drugs designed to cure patients with advanced cancers.

Zacks Rank and Key Picks

Agenus carries a Zacks Rank #2 (Buy).Some other top-ranked health care stocks in the same space include Ligand Pharmaceuticals Inc. (NASDAQ:LGND) , Exelixis, Inc. (NASDAQ:EXEL) and Adaptimmune Therapeutics plc (NASDAQ:ADAP) . While Ligand sports a Zacks Rank #1 (Strong Buy), Exelixis and Adaptimmune carry a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

Ligand’s earnings per share estimates have moved up $3.68 to $3.70 for 2018 over the last 30 days. The company pulled off positive earnings surprises in two of the trailing four quarters, with an average beat of 6.19%. The share price of the company has increased 44% year to date.

Exelixis’ earnings per share estimates have moved up from 26 cents to 45 cents for 2017 and from 63 cents to 70 cents for 2018 over the last 30 days. The company delivered positive earnings surprises in all of the trailing four quarters, with an average beat of 572.92%. The share price of the company has increased 78.3% year to date.

Adaptimmune’s loss per share estimates have narrowed from 96 cents to 76 cents for 2017 and from 90 cents to 74 cents for 2018 over the last 60 days. The company came up with positive earnings surprises in two of the trailing four quarters, with an average beat of 24.79%. The share price of the company has increased 101.7% year to date.

Wall Street’s Next Amazon (NASDAQ:AMZN)

Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time. It’s a once-in-a-generation opportunity to invest in pure genius.

Click for details >>



Exelixis, Inc. (EXEL): Free Stock Analysis Report

Ligand Pharmaceuticals Incorporated (LGND): Free Stock Analysis Report

Agenus Inc. (AGEN): Free Stock Analysis Report

Adaptimmune Therapeutics PLC (ADAP): Free Stock Analysis Report

Original post

Zacks Investment Research

Agenus (AGEN) Reports In Line Loss In Q3, Revenues Lag
 

Related Articles

Agenus (AGEN) Reports In Line Loss In Q3, Revenues Lag

Add a Comment

Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.
  • Any comment you publish, together with your investing.com profile, will be public on investing.com and may be indexed and available through third party search engines, such as Google.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

Write your thoughts here
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Apple
Continue with Google
or
Sign up with Email